Related Experiment Videos
[Clinical efficacy of LAK cell adoptive immunotherapy in advanced cancer patients]
1Department of Surgery, Hiroshima University, Japan.
Clinical efficacy of lymphokine-activated killer (LAK) cell adoptive immunotherapy (AIT) in combination with plasma exchange was investigated as protocol 1 in 24 patients with advanced cancer. For the development of protocol 1, AIT in combination with plasma exchange, OK-432, interleukin-2 (IL-2) and cyclophosphamide was performed as protocol 2, in which LAK cells, OK-432 and IL-2 were administered through the catheter located in the hepatic or bronchial artery. The clinical efficacy of protocol 1 was found in patients with pleural effusion and metastasis to the lung or liver and resulted in 4 partial responses (20%) and 1 minor response of 20 evaluable cases. On the other hand, that of protocol 2 did 1 partial response (20%) in 5 cases. In vitro cytotoxic activity against either Daudi or K 562 tumor cells of peripheral blood lymphocytes from patient given intraaorta administration of OK-432 and IL-2 was tended to increase to be higher than that from nontreated patients. Postoperative immunodepression in esophageal cancer was blocked by AIT, suggesting the usefulness of AIT as a postoperative adjuvant immunotherapy. Thus, target organ of AIT should be limited for better therapeutic effect and the superiority of local AIT in combination with biological response modifiers may be indicated.
Clinical efficacy of lymphokine-activated killer (LAK) cell adoptive immunotherapy (AIT) in combination with plasma exchange was investigated as protocol 1 in 24 patients with advanced cancer. For the development of protocol 1, AIT in combination with plasma exchange, OK-432, interleukin-2 (IL-2) and cyclophosphamide was performed as protocol 2, in which LAK cells, OK-432 and IL-2 were administered through the catheter located in the hepatic or bronchial artery. The clinical efficacy of protocol 1 was found in patients with pleural effusion and metastasis to the lung or liver and resulted in 4 partial responses (20%) and 1 minor response of 20 evaluable cases. On the other hand, that of protocol 2 did 1 partial response (20%) in 5 cases. In vitro cytotoxic activity against either Daudi or K 562 tumor cells of peripheral blood lymphocytes from patient given intraaorta administration of OK-432 and IL-2 was tended to increase to be higher than that from nontreated patients. Postoperative immunodepression in esophageal cancer was blocked by AIT, suggesting the usefulness of AIT as a postoperative adjuvant immunotherapy. Thus, target organ of AIT should be limited for better therapeutic effect and the superiority of local AIT in combination with biological response modifiers may be indicated.